While we have data to support the use of antidepressants, including the selective serotonin reuptake inhibitors (SSRIs) and the serotonin norepinephrine reuptake inhibitors (SNRIs), during pregnancy, most studies have focused on risk of congenital [...]
About 15% of women will experience postpartum depression after the birth of a child. While most of those women will have unipolar depression, a certain number of women will have bipolar depression. At this juncture, [...]
Anxiety symptoms are common during pregnancy and the postpartum period. According to a recent meta-analysis from Fawcett and colleagues, about one out of every five women has at least one type of anxiety disorder [...]
While we have considerable information regarding the teratogenic risk associated with prenatal exposure to various antiepileptic drugs (AEDs), we have considerably less information on the impact of exposure to AEDs on behavioral outcomes in [...]
While we have heard a lot about brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant – SAGE 217 or zuranolone – has been [...]
For many women with bipolar disorder, lamotrigine (Lamictal) is an effective mood stabilizer. Given its favorable reproductive safety profile, lamotrigine is a reasonable option for women who require treatment with a mood stabilizer during pregnancy.  [...]
Clinical Update 2020:Â Lamotrigine (Lamictal) and Pregnancy Maintenance treatment with a mood stabilizer during pregnancy can significantly reduce the risk of relapse in women with bipolar disorder; however, many of the mood stabilizers commonly [...]
We have really enjoyed our weekly virtual rounds. It’s been a great opportunity to meet other perinatal psychiatrists in the community, and discussions with new people always brings up interesting clinical questions. Last week [...]
A recently published article in the American Journal of Public Health has attributed a substantial financial cost to untreated perinatal mood and anxiety disorders among mothers. The study, conducted by researchers with the think [...]
Zuranolone or SAGE-217 is similar to brexanolone (marketed as Zulresso), the medication which was FDA-approved for the treatment of postpartum depression. Zuranolone is a neurosteroid, an analogue of allopregnanolone, which is a positive allosteric [...]
